Feed ADAP
AD

Adaptimmune Therapeutics plc

ADAP · NASDAQ

$0.05 +8.07% (+$0.00)
Piotroski F-Score Weak
0/9
Valuation
-
N/A
P/E N/A
EV/EBITDA N/A
P/FFO N/A
Growth
-
N/A
EPS growth N/A
Rev. growth N/A
Book val. growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
-
N/A
ROIC N/A
ROE N/A
Asset turnover N/A
Debt
-
N/A
Debt/Equity N/A
Current ratio N/A
Debt/Assets N/A
Stability
0 /100
Unstable
Beta 2.49x
Rev. volatility N/A
EPS volatility N/A

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre ADAP
Online

Despre companie

Adaptimmune Therapeutics plc (ADAP) is a biotechnology company focused on the development and commercialization of immunotherapeutic drugs for cancer treatment. The company specializes in developing T-cell receptors (TCRs) and genetically modified T-cells (CAR-T) for therapeutic use in various types of tumors. Adaptimmune aims to create personalized therapeutic approaches that harness the patient's own immune system to fight cancer. With a successful portfolio of clinical studies and a focus on innovation in cancer therapy, shares of Adaptimmune Therapeutics plc (ADAP) may be suitable for investors seeking opportunities in the biotechnology sector with an emphasis on innovative cancer treatments.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Adrian G. Rawcliffe

Employees

506

Headquarters

Abingdon

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.